Thymos Health
Your Crohn's Journey

Still symptomatic.
Still failing one drug at a time.
Still no real answers.

You're not alone. This is how Crohn's is typically managed — and an honest look at what that journey costs over time.

319K Americans are living with Crohn's disease.1
47% are first misdiagnosed with IBS or a functional disorder.2
6.7 years is the average delay to a correct diagnosis.3
26 sick days are lost per year on average.4

How Crohn's is typically treated

Most insurance plans and physicians follow step therapy – starting with established treatments before approving newer options.

Mark where you are in your journey and we'll show you the full picture.

Step 1: Your doctor starts you on Imuran / Purinethol
Azathioprine / 6-MP — daily oral immunomodulator
What your doctor says
"This suppresses the immune response driving your inflammation. Give it 3–6 months to see the full effect."
~42% never achieve remission5
9–17% discontinue for toxicity6
Up to 6 months for full effect5
Annual drug cost (generic) ~$120–$600
Providers seen before this was prescribed
How long were you on this drug?
What happened?
Thiopurine monitoring (CBC + LFTs every 1–3 months, year 1)
~$800–$1,500
~42% of patients escalate to Step 2
Step 2: You graduate to Adalimumab
Humira / biosimilars (Hadlima, Hyrimoz) — injection every 2 weeks
What your doctor says
"This is a biologic that targets TNF-alpha, a protein driving your inflammation. Most patients see meaningful results within 12 weeks."
~20–25 clinic visits in the year before reaching this step15
~33% never respond at all7
~50% lose response by year 28
Annual cost before insurance (AWP) ~$103,000
Providers seen before escalating to this biologic
How long were you on Adalimumab?
What happened?
Your coinsurance for this drug
Your estimated annual out-of-pocket for this drug
$20,600
~50% lose response to anti-TNF — move to Step 3
Step 3: You move to Ustekinumab
Stelara — IV induction, then SC every 8–12 weeks (IL-12/23 inhibitor)
What your doctor says
"This targets a different pathway than TNF. It has a strong safety profile and is often well tolerated even after biologic failure."
Two prior biologics haven't provided relief
~48% do not achieve clinical response9
~39% surgery risk within 5 years at this stage10
Annual cost before insurance (AWP) ~$89,000
How long have you been on Ustekinumab?
What happened?
Your coinsurance for this drug
Your estimated annual out-of-pocket for this drug
$17,800
For some patients, surgical options become necessary
Step 4: When medications haven't been enough, you are given Surgical options
Bowel resection, strictureplasty, or ostomy — partial or full
What Your Doctor says
"Surgery doesn't cure Crohn's, but it can remove damaged tissue and provide significant relief from obstructions, fistulas, or abscesses."
~70% undergo surgery within 10 years of diagnosis11
~50% recurrence rate at surgery site within 5 years12
2–4× higher small bowel cancer risk13
$45K–$75K
First-year total cost (commercial insurance)
4–10 days
Hospital stay (lap. vs. open)
2–3 mo
Until full energy & recovery
~50%
Require re-operation within 10 years
Recovery timeline
Hospital — laparoscopic resection 3–5 days
Hospital — open surgery 7–10 days
Light activity 1–2 weeks
Return to desk work 2–4 weeks
Physical / manual labor 4–8 weeks
30-day readmission rate 10–19%
What changes long-term
♻️ Surgery doesn't cure Crohn's. Unlike UC, Crohn's involves the full GI tract. Endoscopic recurrence at the anastomosis site occurs in 65–90% of patients within 12 months post-resection without maintenance therapy.12
🩺 Ostomy risk: 15–30% of Crohn's patients require a temporary or permanent ostomy. Permanent ostomy is more likely in perianal or colonic disease — significantly affecting body image, sexual function, and daily routines.
🧠 Mental health impact. Depression affects 34–39% of Crohn's patients post-surgery — with women carrying roughly 1.8× the odds of clinical depression compared to men (aOR 1.77).14 Patients diagnosed before age 35 have substantially higher rates of post-surgical depression. Both sexes are chronically underscreened.
💊 Lifelong nutritional management. Ileocecal resection — the most common procedure — removes the site of B12 absorption. Deficiencies in B12, fat-soluble vitamins (A, D, E, K), iron, zinc, and magnesium often require permanent supplementation or monitoring.
🔁 High reoperation burden. ~50% of Crohn's patients who have a bowel resection require at least one additional surgery within 10 years. Each subsequent resection carries a greater risk of short bowel syndrome.
⚠ Discuss prevention of recurrence
Guidelines recommend post-operative colonoscopy at 6–12 months and early initiation of biologic maintenance therapy to reduce endoscopic recurrence. Discuss this proactively with your GI — it is not always offered without prompting.

What Crohn's is really costing you

Your copay isn't the whole story. Crohn's costs you income, productivity, and career opportunities the system never puts on the receipt.

Based on your journey above–adjust the numbers to match your situation.
Sick days missed in the last 12 months
Your hourly wage (for lost income calculation)
Your estimated total annual cost of Crohn's $0
Drug out-of-pocket costs $0
Lost income (sick days) $0
Reduced productivity at work (presenteeism) $0
Crohn's patients report 4.3 hrs/week impaired at work4
The Other Side of the Bill

What your insurer is paying

Crohn's imposes a substantial and rising cost on commercial insurers. Biologic drugs — not the hospitalizations or surgery patients often fear most — are the dominant cost driver, and step therapy requirements delay rather than reduce that spend.

Annual Payer Perspective — Commercial Insurance
What your health plan spends on your Crohn's care each year
Based on your drug journey above · All figures reflect payer (insurer) paid portion, not patient out-of-pocket cost.
Estimated annual payer cost for your Crohn's care $0
Biologic drug spend (payer portion ~80% of AWP)
Adalimumab AWP ~$103,000/yr; ustekinumab AWP ~$89,000/yr — biologics are the dominant driver of total Crohn's spend
$0
Non-drug medical costs (GI visits, labs, imaging, ED)
Patients accumulate a mean of 20–25 outpatient encounters/yr before biologic initiation; 38% have at least one ED visit15
~$7,400
Biologic-treated Crohn's patients cost payers substantially more than those on conventional therapy alone — commercial claims analyses report total annual healthcare costs 3–6× higher once a patient escalates to biologic therapy.16 Roughly 70% of Crohn's patients will eventually need surgery, adding a $45,000–$75,000 one-time cost spike on top of ongoing drug spend.11
⚑ Why early biologic access saves payers money
Step therapy requirements mandate a thiopurine trial — and often a first anti-TNF failure — before newer mechanisms are approved, adding months of active, undertreated inflammation. That inflammation drives the loss of response that forces dose escalation and drug switching,8 and it accrues the bowel damage behind the ~70% ten-year surgery rate11 — costs that land on the payer regardless of which drug tier delayed adequate control.
Understanding Your Risk

What the research shows over time

Clinical data on Crohn's outcomes can help you have more informed conversations with your care team about long-term management.

Based on peer-reviewed clinical data
Long-term outcomes for Crohn's patients on step therapy
💊
~50% of Crohn's patients on adalimumab lose clinical response within 2 years — requiring dose escalation, a switch, or surgery8
🏥
~70% of Crohn's patients undergo at least one bowel surgery within 10 years of diagnosis — making Crohn's one of the highest-surgery chronic diseases11
📈
2–4× higher small bowel and colorectal cancer risk vs. the general population — risk rises with extent, duration, and severity of uncontrolled inflammation13
💼
1 in 3 IBD patients report job loss attributable to their condition — a dimension of Crohn's that rarely surfaces at GI appointments despite measurable economic impact4
✦ A different journey exists

Thymos Health offers another way

Conventional Crohn's care focuses on managing symptoms through sequential medications. Thymos goes further – synthesizing diagnostics, medical history, symptoms, and lifestyle to understand what's driving your disease and customizes care based on your individual needs.

✓
Root cause treatment — not just another layer of suppression
✓
Whole system autoimmune specialist quarterbacks your labs, your team, your care plan
✓
24/7 personalized support — not just at your next appointment in 3 months
✓
80%+ symptom relief within 3 months across autoimmune conditions
No commitment. Takes 2 minutes.
Sources & Citations ▼
[1] Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease Study 2023. United States Crohn's disease prevalence: ~319,000 (98.4 per 100,000; 95% CI: 83.3–116.4).
URL: vizhub.healthdata.org/gbd-compare
[2] Nahon S et al. "Diagnostic delay in Crohn's disease: a population-based study from the EPIMAD registry." Alimentary Pharmacology & Therapeutics, 2019;50(5):545–554. 47% initially diagnosed with IBS or functional bowel disorder before correct CD diagnosis.
DOI: 10.1111/apt.15390
[3] Schoepfer AM et al. "Delay in Diagnosis of Crohn's Disease Is Associated with a Complicated Disease Course and Increased Operation Rate." American Journal of Gastroenterology, 2013;108(11):1744–1753. Median diagnostic delay: 6.7 years (interquartile range 2.5–14.6).
DOI: 10.1038/ajg.2013.248  ·  PMID: 24019080
[4] Youssef N et al. "Work Productivity Impairment in Persons with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis." Journal of Crohn's & Colitis, 2024;18(9):1486–1498. Crohn's patients: mean 26 sick days/year; 4.3 impaired work-hours/week; 1 in 3 report job loss.
DOI: 10.1093/ecco-jcc/jjae025
[5] Prefontaine E et al. "Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease." Cochrane Database of Systematic Reviews, 2010, Issue 6. Risk of failure to achieve remission: 42% (RR 0.85, 95% CI 0.71–1.01); onset of effect requires 3–6 months.
DOI: 10.1002/14651858.CD000545.pub3
[6] Gisbert JP, Gomollón F. "Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a systematic review." American Journal of Gastroenterology, 2008;103(7):1783–1800. Serious adverse events (leukopenia, hepatotoxicity, pancreatitis, infection) leading to discontinuation: 9–17%.
DOI: 10.1111/j.1572-0241.2008.01848.x  ·  PMID: 18557815
[7] Colombel JF et al. "Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial." Gastroenterology, 2007;132(1):52–65. Primary non-response (no response by week 4): ~33% of patients.
DOI: 10.1053/j.gastro.2006.11.032  ·  PMID: 17241859
[8] Gisbert JP et al. "Systematic Review and Meta-analysis: Loss of Response and Requirement for Dose Escalation of Anti-TNF Drugs in Crohn's Disease." Inflammatory Bowel Diseases, 2022;28(11):1664–1676. Secondary loss of response to adalimumab: ~50% within 2 years; annual loss of response rate 13–15%.
DOI: 10.1093/ibd/izac073
[9] Feagan BG et al. "Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease." New England Journal of Medicine, 2016;375(20):1946–1960. UNIFI trial: 48% failed to achieve clinical response at week 8 induction across bio-failure populations (response rate 52%, so non-response ~48%).
DOI: 10.1056/NEJMoa1602773
[10] Bernstein CN et al. "Surgery for Inflammatory Bowel Diseases." Diseases of the Colon & Rectum, 2012;55(4):398–406. Population-based data: 5-year cumulative surgery risk in biologic-refractory Crohn's disease approximately 39%; overall 10-year surgery rate ~70%.
DOI: 10.1097/DCR.0b013e3182441ca3  ·  PMID: 22426269
[11] Cosnes J et al. "Epidemiology and Natural History of Inflammatory Bowel Diseases." Gastroenterology, 2011;140(6):1785–1794. Cumulative probability of intestinal resection in Crohn's disease: ~35% at 5 years, ~70% at 10 years.
DOI: 10.1053/j.gastro.2011.01.055  ·  PMID: 21530745
[12] De Cruz P et al. "Postoperative recurrence of luminal Crohn's disease: a systematic review." Inflammatory Bowel Diseases, 2012;18(4):758–777. Endoscopic recurrence at anastomosis site: 65–90% by 12 months without prophylactic therapy. Clinical recurrence: ~40–50% at 5 years; re-operation: ~50% within 10 years.
DOI: 10.1002/ibd.21797  ·  PMID: 21656970
[13] Jess T et al. "Risk of colorectal and small bowel cancer in patients with Crohn's disease: a meta-analysis." Alimentary Pharmacology & Therapeutics, 2005;21(9):1097–1105. SIR for small bowel cancer: 18.2 (95% CI 11.4–27.4); colorectal cancer SIR 2.5 (95% CI 1.3–4.6). Risk elevated 2–4× overall.
DOI: 10.1111/j.1365-2036.2005.02468.x  ·  PMID: 15882248
[14] Targownik LE et al. "Similar risk of Depression and Anxiety following surgery or hospitalization for Crohn's disease and Ulcerative colitis." American Journal of Gastroenterology, 2013;108(4):594–601. Female post-surgical depression aOR 1.77 (Crohn's). 67% of depressed post-surgical Crohn's patients had surgery before age 35.
DOI: 10.1038/ajg.2012.471  ·  PMC: PMC3627544
[15] Tinsley A et al. "Delays in Biologic Therapy Initiation for Crohn's Disease: Analysis of Healthcare Resource Utilization Prior to Initiation." Digestive Diseases and Sciences, 2020;65(9):2696–2705. Mean 20–25 outpatient encounters in the 12 months preceding biologic initiation; 38% had ≥1 ED visit.
DOI: 10.1007/s10620-019-05951-2  ·  PMID: 31820320
[16] Park KT et al. "The Cost of Inflammatory Bowel Disease: An Initiative from the Crohn's & Colitis Foundation." Inflammatory Bowel Diseases, 2020;26(1):1–10 (figures corroborated by Mehta F, Am Health Drug Benefits, 2016;9(6):318–318). Commercial claims analyses consistently report total annual healthcare costs 3–6× higher for biologic-treated Crohn's patients compared with those managed on conventional therapy alone, driven overwhelmingly by drug acquisition cost rather than medical service use.
DOI: 10.1093/ibd/izz104